Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

The Ad26.RSV.preF/RSV preF protein vaccine has previously demonstrated efficacyin protecting older adults against respiratory syncytial virus (RSV)–related lower respiratory tract disease in a phase 2b study. This study compared the immunogenicity of vaccine clinical trial material (CTM) representat...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Archana Jastorff, Arangassery Rosemary Bastian, Nynke Ligtenberg, Vladislav Klyashtornyy, Benoît Callendret, Esther Heijnen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2024-12-01
coleção:	Human Vaccines & Immunotherapeutics
Assuntos:	Respiratory syncytial virus RSV vaccine Ad26, immunogenicity, Ad26.RSV.preF, RSV preF protein
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2383504
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!